Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 281

1.

Author Correction: Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells.

Fehlings M, Simoni Y, Penny HL, Becht E, Loh CY, Gubin MM, Ward JP, Wong SC, Schreiber RD, Newell EW.

Nat Commun. 2018 Jul 26;9(1):3000. doi: 10.1038/s41467-018-05468-y.

2.

Pillars Article: IFNγ and Lymphocytes Prevent Primary Tumour Development and Shape Tumour Immunogenicity. Nature. 2001. 410: 1107-1111.

Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD.

J Immunol. 2018 Aug 1;201(3):827-831. No abstract available.

PMID:
30038035
3.

Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity.

Alspach E, Lussier DM, Schreiber RD.

Cold Spring Harb Perspect Biol. 2018 Apr 16. pii: a028480. doi: 10.1101/cshperspect.a028480. [Epub ahead of print]

PMID:
29661791
4.

Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma.

Zolkind P, Przybylski D, Marjanovic N, Nguyen L, Lin T, Johanns T, Alexandrov A, Zhou L, Allen CT, Miceli AP, Schreiber RD, Artyomov M, Dunn GP, Uppaluri R.

Oncotarget. 2017 Dec 28;9(3):4109-4119. doi: 10.18632/oncotarget.23751. eCollection 2018 Jan 9.

5.

Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells.

Fehlings M, Simoni Y, Penny HL, Becht E, Loh CY, Gubin MM, Ward JP, Wong SC, Schreiber RD, Newell EW.

Nat Commun. 2017 Sep 15;8(1):562. doi: 10.1038/s41467-017-00627-z. Erratum in: Nat Commun. 2018 Jul 26;9(1):3000.

6.

Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during a mucosal viral infection.

Lee AJ, Chen B, Chew MV, Barra NG, Shenouda MM, Nham T, van Rooijen N, Jordana M, Mossman KL, Schreiber RD, Mack M, Ashkar AA.

J Exp Med. 2017 Apr 3;214(4):1153-1167. doi: 10.1084/jem.20160880. Epub 2017 Mar 6.

7.

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.

Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, Selby MJ, Graziano RF, Mardis ER, Korman AJ, Schreiber RD.

Cancer Immunol Res. 2017 Feb;5(2):106-117. doi: 10.1158/2326-6066.CIR-16-0391. Epub 2017 Jan 10.

8.

Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach.

Johanns TM, Ward JP, Miller CA, Wilson C, Kobayashi DK, Bender D, Fu Y, Alexandrov A, Mardis ER, Artyomov MN, Schreiber RD, Dunn GP.

Cancer Immunol Res. 2016 Dec;4(12):1007-1015. Epub 2016 Oct 31.

9.

Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity.

Putz EM, Majoros A, Gotthardt D, Prchal-Murphy M, Zebedin-Brandl EM, Fux DA, Schlattl A, Schreiber RD, Carotta S, Müller M, Gerner C, Decker T, Sexl V.

Oncoimmunology. 2016 May 19;5(9):e1186314. eCollection 2016.

10.

Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas.

Griffith OL, Chan SR, Griffith M, Krysiak K, Skidmore ZL, Hundal J, Allen JA, Arthur CD, Runci D, Bugatti M, Miceli AP, Schmidt H, Trani L, Kanchi KL, Miller CA, Larson DE, Fulton RS, Vermi W, Wilson RK, Schreiber RD, Mardis ER.

Cell Rep. 2016 Sep 27;17(1):249-260. doi: 10.1016/j.celrep.2016.08.076.

11.

Novel ERα positive breast cancer model with estrogen independent growth in the bone microenvironment.

Capietto AH, Chan SR, Ricci B, Allen JA, Su X, Novack DV, Schreiber RD, Faccio R.

Oncotarget. 2016 Aug 2;7(31):49751-49764. doi: 10.18632/oncotarget.10443.

12.

NKG2D-NKG2D Ligand Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma In Vivo.

Raju S, Kretzmer LZ, Koues OI, Payton JE, Oltz EM, Cashen A, Polic B, Schreiber RD, Shaw AS, Markiewicz MA.

J Immunol. 2016 Jun 1;196(11):4805-13. doi: 10.4049/jimmunol.1501982. Epub 2016 May 2.

13.

Preface.

Schreiber RD.

Adv Immunol. 2016;130:xi-xiii. doi: 10.1016/S0065-2776(16)30010-4. No abstract available.

PMID:
26923005
14.

The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.

Ward JP, Gubin MM, Schreiber RD.

Adv Immunol. 2016;130:25-74. doi: 10.1016/bs.ai.2016.01.001. Epub 2016 Feb 10. Review.

15.

Fresh Beginnings.

Greenberg PD, Schreiber RD, Miller LJ.

Cancer Immunol Res. 2016 Jan;4(1):1-2. doi: 10.1158/2326-6066.CIR-15-0304. No abstract available.

16.

Dual Requirement of Cytokine and Activation Receptor Triggering for Cytotoxic Control of Murine Cytomegalovirus by NK Cells.

Parikh BA, Piersma SJ, Pak-Wittel MA, Yang L, Schreiber RD, Yokoyama WM.

PLoS Pathog. 2015 Dec 31;11(12):e1005323. doi: 10.1371/journal.ppat.1005323. eCollection 2015 Dec.

17.

CANCER. The odds of immunotherapy success.

Gubin MM, Schreiber RD.

Science. 2015 Oct 9;350(6257):158-9. doi: 10.1126/science.aad4140. No abstract available.

PMID:
26450194
18.

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, Tonc E, Schreiber RD, Pearce EJ, Pearce EL.

Cell. 2015 Sep 10;162(6):1229-41. doi: 10.1016/j.cell.2015.08.016. Epub 2015 Aug 27.

19.

Tumor neoantigens: building a framework for personalized cancer immunotherapy.

Gubin MM, Artyomov MN, Mardis ER, Schreiber RD.

J Clin Invest. 2015 Sep;125(9):3413-21. doi: 10.1172/JCI80008. Epub 2015 Aug 10. Review.

20.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

Supplemental Content

Loading ...
Support Center